MENU
+Compare
GTBP
Stock ticker: NASDAQ
AS OF
Jul 22, 01:09 PM (EDT)
Price
$2.01
Change
-$0.01 (-0.50%)
Capitalization
6.61M

GTBP GT Biopharma Forecast, Technical & Fundamental Analysis

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States... Show more

GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GTBP with price predictions
Jul 21, 2025

GTBP in +11.71% Uptrend, rising for three consecutive days on July 10, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GTBP advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GTBP's RSI Indicator exited the oversold zone, of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

GTBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 129 cases where GTBP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GTBP as a result. In of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GTBP turned negative on July 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .

GTBP moved below its 50-day moving average on July 07, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GTBP crossed bearishly below the 50-day moving average on July 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GTBP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.537) is normal, around the industry mean (18.131). P/E Ratio (0.000) is within average values for comparable stocks, (58.574). GTBP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.444). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (274.844).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GTBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GTBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GTBP is expected to report earnings to fall 74.24% to -8 cents per share on March 27

GT Biopharma GTBP Stock Earnings Reports
Q4'23
Est.
$-0.09
Q1'25
Beat
by $0.26
Q3'23
Beat
by $0.03
Q2'23
Beat
by $0.05
Q1'23
Beat
by $0.16
The last earnings report on May 15 showed earnings per share of -33 cents, beating the estimate of -58 cents. With 21.91K shares outstanding, the current market capitalization sits at 6.61M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
8000 Marina Boulevard
Phone
+1 415 919-4040
Employees
2
Web
https://www.gtbiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TTNP4.590.11
+2.40%
Titan Pharmaceuticals
EBMT17.060.09
+0.53%
Eagle Bancorp Montana
RARE26.390.08
+0.30%
Ultragenyx Pharmaceutical
FOXA55.47-0.78
-1.39%
Fox Corp
SEPN12.31-0.24
-1.91%
Septerna Inc

GTBP and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with BDRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then BDRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBP
1D Price
Change %
GTBP100%
-1.94%
BDRX - GTBP
39%
Loosely correlated
+0.69%
SLGL - GTBP
33%
Poorly correlated
+3.57%
TRAW - GTBP
31%
Poorly correlated
+2.50%
RAPT - GTBP
30%
Poorly correlated
+0.17%
PTCT - GTBP
28%
Poorly correlated
+0.48%
More